In the study, electrodes will be implanted in the brain and connected to a stimulator in the chest. Credit: meeboonstudio / Shutterstock.

Abbott has commenced a pivotal clinical trial to assess its deep brain stimulation (DBS) system in managing treatment-resistant depression (TRD).

The Treatment ResistAnt DepressioN Subcallosal CingulatE Network DBS (TRANSCEND) study aims to enrol 100 participants who have not responded to at least four different anti-depressant treatments.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

In this double-blind, sham-controlled, randomised, prospective, multi-centred trial, participants aged 22 to 70 years will be assigned randomly to either the treatment or control arm at up to 25 centres across the nation.

The primary measure of success will be the change in Montgomery-Asberg Depression Rating Scale (MADRS) scores over 12 months.

Following this period, all participants will receive active DBS and be monitored for an additional two years.

See Also:

DBS operates similarly to a pacemaker, delivering targeted electrical pulses to brain areas associated with depression.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

In the TRANSCEND study, electrodes will be implanted in the brain and connected to a stimulator in the chest to alleviate depressive symptoms.

Previous studies have indicated that DBS can lead to a sustained improvement in depression symptoms for a significant proportion of participants over several years.

In 2022, the DBS system secured breakthrough device designation from the US Food and Drug Administration (FDA) to improve treatment for life-threatening or irreversibly debilitating conditions.

Abbott neuromodulation vice-president Pedro Malha said: “Treatment-resistant depression is a debilitating condition affecting 2.8 million Americans each year.

“The goal of Abbott’s TRANSCEND study, in collaboration with top clinical research centres, is to develop the clinical evidence necessary to determine whether DBS is a safe and effective treatment for treatment-resistant depression, which could provide people with a new treatment option that will allow them to live fuller lives.”

Last month, the FDA approved a label change for Abbott’s HeartMate 3 left ventricular assist device, eliminating the need for aspirin use as part of routine patient management.